m6A Regulator and Potential Drug Response

General Information of the m6A Regulator (ID: REG00009)

Regulator Name	Wilms tumor 1-associating protein (WTAP)
Synonyms	Female-lethal(2)D homolog; hFL(2)D; WT1-associated protein; Pre-mRNA-splicing regulator WTAP; KIAA0105 Click to Show/Hide
Gene Name	WTAP
Regulator Type	WRITER ERASER READER
Regulator Link	Click to View Full Information of This Regulator

Full List of Target Gene(s) of This m6A Regulator and Corresponding Potential Drug Response(s)

DNA-binding factor KBF1 (p105)

CAT 1004 [Phase 2]

In total 1 mechanisms lead to this potential drug response		Drug Info
Response Summary	DNA-binding factor KBF1 (p105) is a therapeutic target for CAT 1004. The Wilms tumor 1-associating protein (WTAP) has potential in affecting the response of CAT 1004 through regulating the expression of DNA-binding factor KBF1 (p105).	[1], [2]

P54 [Phase 2]

In total 1 mechanisms lead to this potential drug response		Drug Info
Response Summary	DNA-binding factor KBF1 (p105) is a therapeutic target for P54. The Wilms tumor 1-associating protein (WTAP) has potential in affecting the response of P54 through regulating the expression of DNA-binding factor KBF1 (p105).	[1], [3]

Focal adhesion kinase 1 (FAK)

VS-6063 [Phase 2]

In total 1 mechanisms lead to this potential drug response		Drug Info
Response Summary	Focal adhesion kinase 1 (FAK) is a therapeutic target for VS-6063. The Wilms tumor 1-associating protein (WTAP) has potential in affecting the response of VS-6063 through regulating the expression of Focal adhesion kinase 1 (FAK).	[4], [5]

BI-853520 [Phase 1]

In total 1 mechanisms lead to this potential drug response		Drug Info
Response Summary	Focal adhesion kinase 1 (FAK) is a therapeutic target for BI-853520. The Wilms tumor 1-associating protein (WTAP) has potential in affecting the response of BI-853520 through regulating the expression of Focal adhesion kinase 1 (FAK).	[4], [6]

CEP-37440 [Phase 1]

In total 1 mechanisms lead to this potential drug response		Drug Info
Response Summary	Focal adhesion kinase 1 (FAK) is a therapeutic target for CEP-37440. The Wilms tumor 1-associating protein (WTAP) has potential in affecting the response of CEP-37440 through regulating the expression of Focal adhesion kinase 1 (FAK).	[4], [7]

GSK-2256098 [Phase 1]

In total 1 mechanisms lead to this potential drug response		Drug Info
Response Summary	Focal adhesion kinase 1 (FAK) is a therapeutic target for GSK-2256098. The Wilms tumor 1-associating protein (WTAP) has potential in affecting the response of GSK-2256098 through regulating the expression of Focal adhesion kinase 1 (FAK).	[4], [8]

IN10018 [Phase 1]

In total 1 mechanisms lead to this potential drug response		Drug Info
Response Summary	Focal adhesion kinase 1 (FAK) is a therapeutic target for IN10018. The Wilms tumor 1-associating protein (WTAP) has potential in affecting the response of IN10018 through regulating the expression of Focal adhesion kinase 1 (FAK).	[4], [9]

PF-562271 [Phase 1]

In total 1 mechanisms lead to this potential drug response		Drug Info
Response Summary	Focal adhesion kinase 1 (FAK) is a therapeutic target for PF-562271. The Wilms tumor 1-associating protein (WTAP) has potential in affecting the response of PF-562271 through regulating the expression of Focal adhesion kinase 1 (FAK).	[4], [6]

VS-4718 [Phase 1]

In total 1 mechanisms lead to this potential drug response		Drug Info
Response Summary	Focal adhesion kinase 1 (FAK) is a therapeutic target for VS-4718. The Wilms tumor 1-associating protein (WTAP) has potential in affecting the response of VS-4718 through regulating the expression of Focal adhesion kinase 1 (FAK).	[4], [10]

BMS 536924 [Preclinical]

In total 1 mechanisms lead to this potential drug response		Drug Info
Response Summary	Focal adhesion kinase 1 (FAK) is a therapeutic target for BMS 536924. The Wilms tumor 1-associating protein (WTAP) has potential in affecting the response of BMS 536924 through regulating the expression of Focal adhesion kinase 1 (FAK).	[4], [11]

PF-228 [Investigative]

In total 1 mechanisms lead to this potential drug response		Drug Info
Response Summary	Focal adhesion kinase 1 (FAK) is a therapeutic target for PF-228. The Wilms tumor 1-associating protein (WTAP) has potential in affecting the response of PF-228 through regulating the expression of Focal adhesion kinase 1 (FAK).	[4], [12]

Forkhead box protein M1 (FOXM1)

(D-Arg)(9)-p19(ARF) 26-44 peptide [Investigative]

In total 1 mechanisms lead to this potential drug response		Drug Info
Response Summary	Forkhead box protein M1 (FOXM1) is a therapeutic target for (D-Arg)(9)-p19(ARF) 26-44 peptide. The Wilms tumor 1-associating protein (WTAP) has potential in affecting the response of (D-Arg)(9)-p19(ARF) 26-44 peptide through regulating the expression of Forkhead box protein M1 (FOXM1).	[13], [14]

Helicase-moi messenger RNA (DICER1 mRNA)

ISIS 138612 [Investigative]

In total 1 mechanisms lead to this potential drug response		Drug Info
Response Summary	Helicase-moi messenger RNA (DICER1 mRNA) is a therapeutic target for ISIS 138612. The Wilms tumor 1-associating protein (WTAP) has potential in affecting the response of ISIS 138612 through regulating the expression of Helicase-moi messenger RNA (DICER1 mRNA).	[15], [16]

ISIS 138613 [Investigative]

In total 1 mechanisms lead to this potential drug response		Drug Info
Response Summary	Helicase-moi messenger RNA (DICER1 mRNA) is a therapeutic target for ISIS 138613. The Wilms tumor 1-associating protein (WTAP) has potential in affecting the response of ISIS 138613 through regulating the expression of Helicase-moi messenger RNA (DICER1 mRNA).	[15], [16]

ISIS 138616 [Investigative]

In total 1 mechanisms lead to this potential drug response		Drug Info
Response Summary	Helicase-moi messenger RNA (DICER1 mRNA) is a therapeutic target for ISIS 138616. The Wilms tumor 1-associating protein (WTAP) has potential in affecting the response of ISIS 138616 through regulating the expression of Helicase-moi messenger RNA (DICER1 mRNA).	[15], [16]

ISIS 138647 [Investigative]

In total 1 mechanisms lead to this potential drug response		Drug Info
Response Summary	Helicase-moi messenger RNA (DICER1 mRNA) is a therapeutic target for ISIS 138647. The Wilms tumor 1-associating protein (WTAP) has potential in affecting the response of ISIS 138647 through regulating the expression of Helicase-moi messenger RNA (DICER1 mRNA).	[15], [16]

ISIS 138648 [Investigative]

In total 1 mechanisms lead to this potential drug response		Drug Info
Response Summary	Helicase-moi messenger RNA (DICER1 mRNA) is a therapeutic target for ISIS 138648. The Wilms tumor 1-associating protein (WTAP) has potential in affecting the response of ISIS 138648 through regulating the expression of Helicase-moi messenger RNA (DICER1 mRNA).	[15], [16]

ISIS 138649 [Investigative]

In total 1 mechanisms lead to this potential drug response		Drug Info
Response Summary	Helicase-moi messenger RNA (DICER1 mRNA) is a therapeutic target for ISIS 138649. The Wilms tumor 1-associating protein (WTAP) has potential in affecting the response of ISIS 138649 through regulating the expression of Helicase-moi messenger RNA (DICER1 mRNA).	[15], [16]

ISIS 138678 [Investigative]

In total 1 mechanisms lead to this potential drug response		Drug Info
Response Summary	Helicase-moi messenger RNA (DICER1 mRNA) is a therapeutic target for ISIS 138678. The Wilms tumor 1-associating protein (WTAP) has potential in affecting the response of ISIS 138678 through regulating the expression of Helicase-moi messenger RNA (DICER1 mRNA).	[15], [17]

Hexokinase-2 (HK2)

VDA-1102 [Phase 2]

In total 1 mechanisms lead to this potential drug response		Drug Info
Response Summary	Hexokinase-2 (HK2) is a therapeutic target for VDA-1102. The Wilms tumor 1-associating protein (WTAP) has potential in affecting the response of VDA-1102 through regulating the expression of Hexokinase-2 (HK2).	[18], [19]

Janus kinase 3 (JAK-3)

Tofacitinib [Approved]

In total 1 mechanisms lead to this potential drug response		Drug Info
Response Summary	Janus kinase 3 (JAK-3) is a therapeutic target for Tofacitinib. The Wilms tumor 1-associating protein (WTAP) has potential in affecting the response of Tofacitinib through regulating the expression of Janus kinase 3 (JAK-3).	[5], [20]

ASP-015K [Phase 3]

In total 1 mechanisms lead to this potential drug response		Drug Info
Response Summary	Janus kinase 3 (JAK-3) is a therapeutic target for ASP-015K. The Wilms tumor 1-associating protein (WTAP) has potential in affecting the response of ASP-015K through regulating the expression of Janus kinase 3 (JAK-3).	[20], [21]

PF-06651600 [Phase 2/3]

In total 1 mechanisms lead to this potential drug response		Drug Info
Response Summary	Janus kinase 3 (JAK-3) is a therapeutic target for PF-06651600. The Wilms tumor 1-associating protein (WTAP) has potential in affecting the response of PF-06651600 through regulating the expression of Janus kinase 3 (JAK-3).	[20], [22]

VX-509 [Phase 2/3]

In total 1 mechanisms lead to this potential drug response		Drug Info
Response Summary	Janus kinase 3 (JAK-3) is a therapeutic target for VX-509. The Wilms tumor 1-associating protein (WTAP) has potential in affecting the response of VX-509 through regulating the expression of Janus kinase 3 (JAK-3).	[20], [23]

ATI-501 [Phase 2]

In total 1 mechanisms lead to this potential drug response		Drug Info
Response Summary	Janus kinase 3 (JAK-3) is a therapeutic target for ATI-501. The Wilms tumor 1-associating protein (WTAP) has potential in affecting the response of ATI-501 through regulating the expression of Janus kinase 3 (JAK-3).	[20], [24]

ATI-502 [Phase 2]

In total 1 mechanisms lead to this potential drug response		Drug Info
Response Summary	Janus kinase 3 (JAK-3) is a therapeutic target for ATI-502. The Wilms tumor 1-associating protein (WTAP) has potential in affecting the response of ATI-502 through regulating the expression of Janus kinase 3 (JAK-3).	[20], [25]

Cerdulatinib [Phase 2]

In total 1 mechanisms lead to this potential drug response		Drug Info
Response Summary	Janus kinase 3 (JAK-3) is a therapeutic target for Cerdulatinib. The Wilms tumor 1-associating protein (WTAP) has potential in affecting the response of Cerdulatinib through regulating the expression of Janus kinase 3 (JAK-3).	[20], [26]

SNA-125 [Phase 1]

In total 1 mechanisms lead to this potential drug response		Drug Info
Response Summary	Janus kinase 3 (JAK-3) is a therapeutic target for SNA-125. The Wilms tumor 1-associating protein (WTAP) has potential in affecting the response of SNA-125 through regulating the expression of Janus kinase 3 (JAK-3).	[20], [24]

6-o-tolylquinazolin-2-amine [Investigative]

In total 1 mechanisms lead to this potential drug response		Drug Info
Response Summary	Janus kinase 3 (JAK-3) is a therapeutic target for 6-o-tolylquinazolin-2-amine. The Wilms tumor 1-associating protein (WTAP) has potential in affecting the response of 6-o-tolylquinazolin-2-amine through regulating the expression of Janus kinase 3 (JAK-3).	[20], [27]

AD-412 [Investigative]

In total 1 mechanisms lead to this potential drug response		Drug Info
Response Summary	Janus kinase 3 (JAK-3) is a therapeutic target for AD-412. The Wilms tumor 1-associating protein (WTAP) has potential in affecting the response of AD-412 through regulating the expression of Janus kinase 3 (JAK-3).	[20], [23]

Atropisomer 1 [Investigative]

In total 1 mechanisms lead to this potential drug response		Drug Info
Response Summary	Janus kinase 3 (JAK-3) is a therapeutic target for Atropisomer 1. The Wilms tumor 1-associating protein (WTAP) has potential in affecting the response of Atropisomer 1 through regulating the expression of Janus kinase 3 (JAK-3).	[20], [28]

CMP-6 [Investigative]

In total 1 mechanisms lead to this potential drug response		Drug Info
Response Summary	Janus kinase 3 (JAK-3) is a therapeutic target for CMP-6. The Wilms tumor 1-associating protein (WTAP) has potential in affecting the response of CMP-6 through regulating the expression of Janus kinase 3 (JAK-3).	[20], [29]

NC1153 [Investigative]

In total 1 mechanisms lead to this potential drug response		Drug Info
Response Summary	Janus kinase 3 (JAK-3) is a therapeutic target for NC1153. The Wilms tumor 1-associating protein (WTAP) has potential in affecting the response of NC1153 through regulating the expression of Janus kinase 3 (JAK-3).	[20], [30]

PF-956980 [Investigative]

In total 1 mechanisms lead to this potential drug response		Drug Info
Response Summary	Janus kinase 3 (JAK-3) is a therapeutic target for PF-956980. The Wilms tumor 1-associating protein (WTAP) has potential in affecting the response of PF-956980 through regulating the expression of Janus kinase 3 (JAK-3).	[20], [23]

VX-467 [Investigative]

In total 1 mechanisms lead to this potential drug response		Drug Info
Response Summary	Janus kinase 3 (JAK-3) is a therapeutic target for VX-467. The Wilms tumor 1-associating protein (WTAP) has potential in affecting the response of VX-467 through regulating the expression of Janus kinase 3 (JAK-3).	[20], [31]

WHI-P154 [Investigative]

In total 1 mechanisms lead to this potential drug response		Drug Info
Response Summary	Janus kinase 3 (JAK-3) is a therapeutic target for WHI-P154. The Wilms tumor 1-associating protein (WTAP) has potential in affecting the response of WHI-P154 through regulating the expression of Janus kinase 3 (JAK-3).	[20], [32]

ZM-39923 [Investigative]

In total 1 mechanisms lead to this potential drug response		Drug Info
Response Summary	Janus kinase 3 (JAK-3) is a therapeutic target for ZM-39923. The Wilms tumor 1-associating protein (WTAP) has potential in affecting the response of ZM-39923 through regulating the expression of Janus kinase 3 (JAK-3).	[20], [33]

AG490 [Terminated]

In total 1 mechanisms lead to this potential drug response		Drug Info
Response Summary	Janus kinase 3 (JAK-3) is a therapeutic target for AG490. The Wilms tumor 1-associating protein (WTAP) has potential in affecting the response of AG490 through regulating the expression of Janus kinase 3 (JAK-3).	[20], [24]

PNU156804 [Terminated]

In total 1 mechanisms lead to this potential drug response		Drug Info
Response Summary	Janus kinase 3 (JAK-3) is a therapeutic target for PNU156804. The Wilms tumor 1-associating protein (WTAP) has potential in affecting the response of PNU156804 through regulating the expression of Janus kinase 3 (JAK-3).	[20], [34]

R348 [Terminated]

In total 1 mechanisms lead to this potential drug response		Drug Info
Response Summary	Janus kinase 3 (JAK-3) is a therapeutic target for R348. The Wilms tumor 1-associating protein (WTAP) has potential in affecting the response of R348 through regulating the expression of Janus kinase 3 (JAK-3).	[20], [35]

Mammalian target of rapamycin complex 1 (mTORC1)

RBT-101 [Phase 3]

In total 1 mechanisms lead to this potential drug response		Drug Info
Response Summary	Mammalian target of rapamycin complex 1 (mTORC1) is a therapeutic target for RBT-101. The Wilms tumor 1-associating protein (WTAP) has potential in affecting the response of RBT-101 through regulating the expression of Mammalian target of rapamycin complex 1 (mTORC1).	[36], [37]

AZD-2014 [Phase 2]

In total 1 mechanisms lead to this potential drug response		Drug Info
Response Summary	Mammalian target of rapamycin complex 1 (mTORC1) is a therapeutic target for AZD-2014. The Wilms tumor 1-associating protein (WTAP) has potential in affecting the response of AZD-2014 through regulating the expression of Mammalian target of rapamycin complex 1 (mTORC1).	[36], [38]

ME-344 [Phase 1/2]

In total 1 mechanisms lead to this potential drug response		Drug Info
Response Summary	Mammalian target of rapamycin complex 1 (mTORC1) is a therapeutic target for ME-344. The Wilms tumor 1-associating protein (WTAP) has potential in affecting the response of ME-344 through regulating the expression of Mammalian target of rapamycin complex 1 (mTORC1).	[36], [39]

NV-5138 [Phase 1]

In total 1 mechanisms lead to this potential drug response		Drug Info
Response Summary	Mammalian target of rapamycin complex 1 (mTORC1) is a therapeutic target for NV-5138. The Wilms tumor 1-associating protein (WTAP) has potential in affecting the response of NV-5138 through regulating the expression of Mammalian target of rapamycin complex 1 (mTORC1).	[36], [40]

Palomid-529 [Phase 1]

In total 1 mechanisms lead to this potential drug response		Drug Info
Response Summary	Mammalian target of rapamycin complex 1 (mTORC1) is a therapeutic target for Palomid-529. The Wilms tumor 1-associating protein (WTAP) has potential in affecting the response of Palomid-529 through regulating the expression of Mammalian target of rapamycin complex 1 (mTORC1).	[36], [39]

VS-5584 [Phase 1]

In total 1 mechanisms lead to this potential drug response		Drug Info
Response Summary	Mammalian target of rapamycin complex 1 (mTORC1) is a therapeutic target for VS-5584. The Wilms tumor 1-associating protein (WTAP) has potential in affecting the response of VS-5584 through regulating the expression of Mammalian target of rapamycin complex 1 (mTORC1).	[36], [41]

Peroxisome proliferator-activated receptor alpha (PPARA)

Bezafibrate [Approved]

In total 1 mechanisms lead to this potential drug response		Drug Info
Response Summary	Peroxisome proliferator-activated receptor alpha (PPARA) is a therapeutic target for Bezafibrate. The Wilms tumor 1-associating protein (WTAP) has potential in affecting the response of Bezafibrate through regulating the expression of Peroxisome proliferator-activated receptor alpha (PPARA).	[42], [43]

Ciprofibrate [Approved]

In total 1 mechanisms lead to this potential drug response		Drug Info
Response Summary	Peroxisome proliferator-activated receptor alpha (PPARA) is a therapeutic target for Ciprofibrate. The Wilms tumor 1-associating protein (WTAP) has potential in affecting the response of Ciprofibrate through regulating the expression of Peroxisome proliferator-activated receptor alpha (PPARA).	[42], [44]

Fenofibrate [Approved]

In total 1 mechanisms lead to this potential drug response		Drug Info
Response Summary	Peroxisome proliferator-activated receptor alpha (PPARA) is a therapeutic target for Fenofibrate. The Wilms tumor 1-associating protein (WTAP) has potential in affecting the response of Fenofibrate through regulating the expression of Peroxisome proliferator-activated receptor alpha (PPARA).	[42], [45]

Lobeglitazone [Approved]

In total 1 mechanisms lead to this potential drug response		Drug Info
Response Summary	Peroxisome proliferator-activated receptor alpha (PPARA) is a therapeutic target for Lobeglitazone. The Wilms tumor 1-associating protein (WTAP) has potential in affecting the response of Lobeglitazone through regulating the expression of Peroxisome proliferator-activated receptor alpha (PPARA).	[42], [46]

Pemafibrate [Approved]

In total 1 mechanisms lead to this potential drug response		Drug Info
Response Summary	Peroxisome proliferator-activated receptor alpha (PPARA) is a therapeutic target for Pemafibrate. The Wilms tumor 1-associating protein (WTAP) has potential in affecting the response of Pemafibrate through regulating the expression of Peroxisome proliferator-activated receptor alpha (PPARA).	[42], [43]

BMS-298585 [Phase 3]

In total 1 mechanisms lead to this potential drug response		Drug Info
Response Summary	Peroxisome proliferator-activated receptor alpha (PPARA) is a therapeutic target for BMS-298585. The Wilms tumor 1-associating protein (WTAP) has potential in affecting the response of BMS-298585 through regulating the expression of Peroxisome proliferator-activated receptor alpha (PPARA).	[37], [42]

CS-038 [Phase 3]

In total 1 mechanisms lead to this potential drug response		Drug Info
Response Summary	Peroxisome proliferator-activated receptor alpha (PPARA) is a therapeutic target for CS-038. The Wilms tumor 1-associating protein (WTAP) has potential in affecting the response of CS-038 through regulating the expression of Peroxisome proliferator-activated receptor alpha (PPARA).	[42], [47]

GFT-505 [Phase 3]

In total 1 mechanisms lead to this potential drug response		Drug Info
Response Summary	Peroxisome proliferator-activated receptor alpha (PPARA) is a therapeutic target for GFT-505. The Wilms tumor 1-associating protein (WTAP) has potential in affecting the response of GFT-505 through regulating the expression of Peroxisome proliferator-activated receptor alpha (PPARA).	[42], [48]

Imiglitazar [Phase 3]

In total 1 mechanisms lead to this potential drug response		Drug Info
Response Summary	Peroxisome proliferator-activated receptor alpha (PPARA) is a therapeutic target for Imiglitazar. The Wilms tumor 1-associating protein (WTAP) has potential in affecting the response of Imiglitazar through regulating the expression of Peroxisome proliferator-activated receptor alpha (PPARA).	[42], [49]

Ragaglitazar [Phase 3]

In total 1 mechanisms lead to this potential drug response		Drug Info
Response Summary	Peroxisome proliferator-activated receptor alpha (PPARA) is a therapeutic target for Ragaglitazar. The Wilms tumor 1-associating protein (WTAP) has potential in affecting the response of Ragaglitazar through regulating the expression of Peroxisome proliferator-activated receptor alpha (PPARA).	[42], [50]

TESAGLITAZAR [Phase 3]

In total 1 mechanisms lead to this potential drug response		Drug Info
Response Summary	Peroxisome proliferator-activated receptor alpha (PPARA) is a therapeutic target for TESAGLITAZAR. The Wilms tumor 1-associating protein (WTAP) has potential in affecting the response of TESAGLITAZAR through regulating the expression of Peroxisome proliferator-activated receptor alpha (PPARA).	[42], [51]

ZYH-1 [Phase 3]

In total 1 mechanisms lead to this potential drug response		Drug Info
Response Summary	Peroxisome proliferator-activated receptor alpha (PPARA) is a therapeutic target for ZYH-1. The Wilms tumor 1-associating protein (WTAP) has potential in affecting the response of ZYH-1 through regulating the expression of Peroxisome proliferator-activated receptor alpha (PPARA).	[42], [52]

GFT14 [Phase 2]

In total 1 mechanisms lead to this potential drug response		Drug Info
Response Summary	Peroxisome proliferator-activated receptor alpha (PPARA) is a therapeutic target for GFT14. The Wilms tumor 1-associating protein (WTAP) has potential in affecting the response of GFT14 through regulating the expression of Peroxisome proliferator-activated receptor alpha (PPARA).	[42], [53]

LY-518674 [Phase 2]

In total 1 mechanisms lead to this potential drug response		Drug Info
Response Summary	Peroxisome proliferator-activated receptor alpha (PPARA) is a therapeutic target for LY-518674. The Wilms tumor 1-associating protein (WTAP) has potential in affecting the response of LY-518674 through regulating the expression of Peroxisome proliferator-activated receptor alpha (PPARA).	[42], [54]

Naveglitazar [Phase 2]

In total 1 mechanisms lead to this potential drug response		Drug Info
Response Summary	Peroxisome proliferator-activated receptor alpha (PPARA) is a therapeutic target for Naveglitazar. The Wilms tumor 1-associating protein (WTAP) has potential in affecting the response of Naveglitazar through regulating the expression of Peroxisome proliferator-activated receptor alpha (PPARA).	[6], [42]

ONO-5129 [Phase 2]

In total 1 mechanisms lead to this potential drug response		Drug Info
Response Summary	Peroxisome proliferator-activated receptor alpha (PPARA) is a therapeutic target for ONO-5129. The Wilms tumor 1-associating protein (WTAP) has potential in affecting the response of ONO-5129 through regulating the expression of Peroxisome proliferator-activated receptor alpha (PPARA).	[42], [55]

ZYH7 [Phase 2]

In total 1 mechanisms lead to this potential drug response		Drug Info
Response Summary	Peroxisome proliferator-activated receptor alpha (PPARA) is a therapeutic target for ZYH7. The Wilms tumor 1-associating protein (WTAP) has potential in affecting the response of ZYH7 through regulating the expression of Peroxisome proliferator-activated receptor alpha (PPARA).	[42], [56]

AVE0897 [Phase 1]

In total 1 mechanisms lead to this potential drug response		Drug Info
Response Summary	Peroxisome proliferator-activated receptor alpha (PPARA) is a therapeutic target for AVE0897. The Wilms tumor 1-associating protein (WTAP) has potential in affecting the response of AVE0897 through regulating the expression of Peroxisome proliferator-activated receptor alpha (PPARA).	[42], [57]

CDT-fenofibrate [Phase 1]

In total 1 mechanisms lead to this potential drug response		Drug Info
Response Summary	Peroxisome proliferator-activated receptor alpha (PPARA) is a therapeutic target for CDT-fenofibrate. The Wilms tumor 1-associating protein (WTAP) has potential in affecting the response of CDT-fenofibrate through regulating the expression of Peroxisome proliferator-activated receptor alpha (PPARA).	[42], [58]

GW-409544 [Phase 1]

In total 1 mechanisms lead to this potential drug response		Drug Info
Response Summary	Peroxisome proliferator-activated receptor alpha (PPARA) is a therapeutic target for GW-409544. The Wilms tumor 1-associating protein (WTAP) has potential in affecting the response of GW-409544 through regulating the expression of Peroxisome proliferator-activated receptor alpha (PPARA).	[42], [59]

Oxeglitazar [Phase 1]

In total 1 mechanisms lead to this potential drug response		Drug Info
Response Summary	Peroxisome proliferator-activated receptor alpha (PPARA) is a therapeutic target for Oxeglitazar. The Wilms tumor 1-associating protein (WTAP) has potential in affecting the response of Oxeglitazar through regulating the expression of Peroxisome proliferator-activated receptor alpha (PPARA).	[42], [60]

TPST-1120 [Phase 1]

In total 1 mechanisms lead to this potential drug response		Drug Info
Response Summary	Peroxisome proliferator-activated receptor alpha (PPARA) is a therapeutic target for TPST-1120. The Wilms tumor 1-associating protein (WTAP) has potential in affecting the response of TPST-1120 through regulating the expression of Peroxisome proliferator-activated receptor alpha (PPARA).	[42], [61]

MC-3001 [Preclinical]

In total 1 mechanisms lead to this potential drug response		Drug Info
Response Summary	Peroxisome proliferator-activated receptor alpha (PPARA) is a therapeutic target for MC-3001. The Wilms tumor 1-associating protein (WTAP) has potential in affecting the response of MC-3001 through regulating the expression of Peroxisome proliferator-activated receptor alpha (PPARA).	[42], [62]

MC-3002 [Preclinical]

In total 1 mechanisms lead to this potential drug response		Drug Info
Response Summary	Peroxisome proliferator-activated receptor alpha (PPARA) is a therapeutic target for MC-3002. The Wilms tumor 1-associating protein (WTAP) has potential in affecting the response of MC-3002 through regulating the expression of Peroxisome proliferator-activated receptor alpha (PPARA).	[42], [63]

PIRINIXIC ACID [Preclinical]

In total 1 mechanisms lead to this potential drug response		Drug Info
Response Summary	Peroxisome proliferator-activated receptor alpha (PPARA) is a therapeutic target for PIRINIXIC ACID. The Wilms tumor 1-associating protein (WTAP) has potential in affecting the response of PIRINIXIC ACID through regulating the expression of Peroxisome proliferator-activated receptor alpha (PPARA).	[42], [64]

Romazarit [Preclinical]

In total 1 mechanisms lead to this potential drug response		Drug Info
Response Summary	Peroxisome proliferator-activated receptor alpha (PPARA) is a therapeutic target for Romazarit. The Wilms tumor 1-associating protein (WTAP) has potential in affecting the response of Romazarit through regulating the expression of Peroxisome proliferator-activated receptor alpha (PPARA).	[6], [42]

(9Z,12E)-12-nitrooctadeca-9,12-dienoic acid [Investigative]

In total 1 mechanisms lead to this potential drug response		Drug Info
Response Summary	Peroxisome proliferator-activated receptor alpha (PPARA) is a therapeutic target for (9Z,12E)-12-nitrooctadeca-9,12-dienoic acid. The Wilms tumor 1-associating protein (WTAP) has potential in affecting the response of (9Z,12E)-12-nitrooctadeca-9,12-dienoic acid through regulating the expression of Peroxisome proliferator-activated receptor alpha (PPARA).	[42], [65]

(E)-12-Nitrooctadec-12-enoic Acid [Investigative]

In total 1 mechanisms lead to this potential drug response		Drug Info
Response Summary	Peroxisome proliferator-activated receptor alpha (PPARA) is a therapeutic target for (E)-12-Nitrooctadec-12-enoic Acid. The Wilms tumor 1-associating protein (WTAP) has potential in affecting the response of (E)-12-Nitrooctadec-12-enoic Acid through regulating the expression of Peroxisome proliferator-activated receptor alpha (PPARA).	[42], [66]

(E)-13-Nitrooctadec-12-enoic Acid [Investigative]

In total 1 mechanisms lead to this potential drug response		Drug Info
Response Summary	Peroxisome proliferator-activated receptor alpha (PPARA) is a therapeutic target for (E)-13-Nitrooctadec-12-enoic Acid. The Wilms tumor 1-associating protein (WTAP) has potential in affecting the response of (E)-13-Nitrooctadec-12-enoic Acid through regulating the expression of Peroxisome proliferator-activated receptor alpha (PPARA).	[42], [66]

(E)-4-(3,5-dimethoxystyryl)phenol [Investigative]

In total 1 mechanisms lead to this potential drug response		Drug Info
Response Summary	Peroxisome proliferator-activated receptor alpha (PPARA) is a therapeutic target for (E)-4-(3,5-dimethoxystyryl)phenol. The Wilms tumor 1-associating protein (WTAP) has potential in affecting the response of (E)-4-(3,5-dimethoxystyryl)phenol through regulating the expression of Peroxisome proliferator-activated receptor alpha (PPARA).	[42], [67]

8S-HETE [Investigative]

In total 1 mechanisms lead to this potential drug response		Drug Info
Response Summary	Peroxisome proliferator-activated receptor alpha (PPARA) is a therapeutic target for 8S-HETE. The Wilms tumor 1-associating protein (WTAP) has potential in affecting the response of 8S-HETE through regulating the expression of Peroxisome proliferator-activated receptor alpha (PPARA).	[42], [52]

AD-5061 [Investigative]

In total 1 mechanisms lead to this potential drug response		Drug Info
Response Summary	Peroxisome proliferator-activated receptor alpha (PPARA) is a therapeutic target for AD-5061. The Wilms tumor 1-associating protein (WTAP) has potential in affecting the response of AD-5061 through regulating the expression of Peroxisome proliferator-activated receptor alpha (PPARA).	[42], [68]

BMS-687453 [Investigative]

In total 1 mechanisms lead to this potential drug response		Drug Info
Response Summary	Peroxisome proliferator-activated receptor alpha (PPARA) is a therapeutic target for BMS-687453. The Wilms tumor 1-associating protein (WTAP) has potential in affecting the response of BMS-687453 through regulating the expression of Peroxisome proliferator-activated receptor alpha (PPARA).	[42], [69]

CP-775146 [Investigative]

In total 1 mechanisms lead to this potential drug response		Drug Info
Response Summary	Peroxisome proliferator-activated receptor alpha (PPARA) is a therapeutic target for CP-775146. The Wilms tumor 1-associating protein (WTAP) has potential in affecting the response of CP-775146 through regulating the expression of Peroxisome proliferator-activated receptor alpha (PPARA).	[42], [70]

DB-900 [Investigative]

In total 1 mechanisms lead to this potential drug response		Drug Info
Response Summary	Peroxisome proliferator-activated receptor alpha (PPARA) is a therapeutic target for DB-900. The Wilms tumor 1-associating protein (WTAP) has potential in affecting the response of DB-900 through regulating the expression of Peroxisome proliferator-activated receptor alpha (PPARA).	[42], [71]

Deoxy-Bigchap [Investigative]

In total 1 mechanisms lead to this potential drug response		Drug Info
Response Summary	Peroxisome proliferator-activated receptor alpha (PPARA) is a therapeutic target for Deoxy-Bigchap. The Wilms tumor 1-associating protein (WTAP) has potential in affecting the response of Deoxy-Bigchap through regulating the expression of Peroxisome proliferator-activated receptor alpha (PPARA).	[42], [72]

DRF 2519 [Investigative]

In total 1 mechanisms lead to this potential drug response		Drug Info
Response Summary	Peroxisome proliferator-activated receptor alpha (PPARA) is a therapeutic target for DRF 2519. The Wilms tumor 1-associating protein (WTAP) has potential in affecting the response of DRF 2519 through regulating the expression of Peroxisome proliferator-activated receptor alpha (PPARA).	[42], [73]

eicosatetranoic acid [Investigative]

In total 1 mechanisms lead to this potential drug response		Drug Info
Response Summary	Peroxisome proliferator-activated receptor alpha (PPARA) is a therapeutic target for eicosatetranoic acid. The Wilms tumor 1-associating protein (WTAP) has potential in affecting the response of eicosatetranoic acid through regulating the expression of Peroxisome proliferator-activated receptor alpha (PPARA).	[42], [74]

Fibrates [Investigative]

In total 1 mechanisms lead to this potential drug response		Drug Info
Response Summary	Peroxisome proliferator-activated receptor alpha (PPARA) is a therapeutic target for Fibrates. The Wilms tumor 1-associating protein (WTAP) has potential in affecting the response of Fibrates through regulating the expression of Peroxisome proliferator-activated receptor alpha (PPARA).	[42], [75]

GSK-9578 [Investigative]

In total 1 mechanisms lead to this potential drug response		Drug Info
Response Summary	Peroxisome proliferator-activated receptor alpha (PPARA) is a therapeutic target for GSK-9578. The Wilms tumor 1-associating protein (WTAP) has potential in affecting the response of GSK-9578 through regulating the expression of Peroxisome proliferator-activated receptor alpha (PPARA).	[42], [66]

GW-2331 [Investigative]

In total 1 mechanisms lead to this potential drug response		Drug Info
Response Summary	Peroxisome proliferator-activated receptor alpha (PPARA) is a therapeutic target for GW-2331. The Wilms tumor 1-associating protein (WTAP) has potential in affecting the response of GW-2331 through regulating the expression of Peroxisome proliferator-activated receptor alpha (PPARA).	[42], [76]

GW7647 [Investigative]

In total 1 mechanisms lead to this potential drug response		Drug Info
Response Summary	Peroxisome proliferator-activated receptor alpha (PPARA) is a therapeutic target for GW7647. The Wilms tumor 1-associating protein (WTAP) has potential in affecting the response of GW7647 through regulating the expression of Peroxisome proliferator-activated receptor alpha (PPARA).	[42], [77]

L-165461 [Investigative]

In total 1 mechanisms lead to this potential drug response		Drug Info
Response Summary	Peroxisome proliferator-activated receptor alpha (PPARA) is a therapeutic target for L-165461. The Wilms tumor 1-associating protein (WTAP) has potential in affecting the response of L-165461 through regulating the expression of Peroxisome proliferator-activated receptor alpha (PPARA).	[42], [75]

L-796449 [Investigative]

In total 1 mechanisms lead to this potential drug response		Drug Info
Response Summary	Peroxisome proliferator-activated receptor alpha (PPARA) is a therapeutic target for L-796449. The Wilms tumor 1-associating protein (WTAP) has potential in affecting the response of L-796449 through regulating the expression of Peroxisome proliferator-activated receptor alpha (PPARA).	[42], [43]

LL-6531 [Investigative]

In total 1 mechanisms lead to this potential drug response		Drug Info
Response Summary	Peroxisome proliferator-activated receptor alpha (PPARA) is a therapeutic target for LL-6531. The Wilms tumor 1-associating protein (WTAP) has potential in affecting the response of LL-6531 through regulating the expression of Peroxisome proliferator-activated receptor alpha (PPARA).	[42], [78]

LY-465608 [Investigative]

In total 1 mechanisms lead to this potential drug response		Drug Info
Response Summary	Peroxisome proliferator-activated receptor alpha (PPARA) is a therapeutic target for LY-465608. The Wilms tumor 1-associating protein (WTAP) has potential in affecting the response of LY-465608 through regulating the expression of Peroxisome proliferator-activated receptor alpha (PPARA).	[42], [79]

N-oleoylethanolamide [Investigative]

In total 1 mechanisms lead to this potential drug response		Drug Info
Response Summary	Peroxisome proliferator-activated receptor alpha (PPARA) is a therapeutic target for N-oleoylethanolamide. The Wilms tumor 1-associating protein (WTAP) has potential in affecting the response of N-oleoylethanolamide through regulating the expression of Peroxisome proliferator-activated receptor alpha (PPARA).	[42], [80]

pristanic acid [Investigative]

In total 1 mechanisms lead to this potential drug response		Drug Info
Response Summary	Peroxisome proliferator-activated receptor alpha (PPARA) is a therapeutic target for pristanic acid. The Wilms tumor 1-associating protein (WTAP) has potential in affecting the response of pristanic acid through regulating the expression of Peroxisome proliferator-activated receptor alpha (PPARA).	[42], [81]

reglitazar [Investigative]

In total 1 mechanisms lead to this potential drug response		Drug Info
Response Summary	Peroxisome proliferator-activated receptor alpha (PPARA) is a therapeutic target for reglitazar. The Wilms tumor 1-associating protein (WTAP) has potential in affecting the response of reglitazar through regulating the expression of Peroxisome proliferator-activated receptor alpha (PPARA).	[42], [82]

TZD18 [Investigative]

In total 1 mechanisms lead to this potential drug response		Drug Info
Response Summary	Peroxisome proliferator-activated receptor alpha (PPARA) is a therapeutic target for TZD18. The Wilms tumor 1-associating protein (WTAP) has potential in affecting the response of TZD18 through regulating the expression of Peroxisome proliferator-activated receptor alpha (PPARA).	[42], [83]

ZY H2 [Investigative]

In total 1 mechanisms lead to this potential drug response		Drug Info
Response Summary	Peroxisome proliferator-activated receptor alpha (PPARA) is a therapeutic target for ZY H2. The Wilms tumor 1-associating protein (WTAP) has potential in affecting the response of ZY H2 through regulating the expression of Peroxisome proliferator-activated receptor alpha (PPARA).	[42], [84]

Aleglitazar [Discontinued in Phase 3]

In total 1 mechanisms lead to this potential drug response		Drug Info
Response Summary	Peroxisome proliferator-activated receptor alpha (PPARA) is a therapeutic target for Aleglitazar. The Wilms tumor 1-associating protein (WTAP) has potential in affecting the response of Aleglitazar through regulating the expression of Peroxisome proliferator-activated receptor alpha (PPARA).	[42], [85]

AR-H049020 [Discontinued in Phase 1]

In total 1 mechanisms lead to this potential drug response		Drug Info
Response Summary	Peroxisome proliferator-activated receptor alpha (PPARA) is a therapeutic target for AR-H049020. The Wilms tumor 1-associating protein (WTAP) has potential in affecting the response of AR-H049020 through regulating the expression of Peroxisome proliferator-activated receptor alpha (PPARA).	[42], [81]

AVE-0847 [Discontinued in Phase 2]

In total 1 mechanisms lead to this potential drug response		Drug Info
Response Summary	Peroxisome proliferator-activated receptor alpha (PPARA) is a therapeutic target for AVE-0847. The Wilms tumor 1-associating protein (WTAP) has potential in affecting the response of AVE-0847 through regulating the expression of Peroxisome proliferator-activated receptor alpha (PPARA).	[42], [86]

AVE-8134 [Discontinued in Phase 2]

In total 1 mechanisms lead to this potential drug response		Drug Info
Response Summary	Peroxisome proliferator-activated receptor alpha (PPARA) is a therapeutic target for AVE-8134. The Wilms tumor 1-associating protein (WTAP) has potential in affecting the response of AVE-8134 through regulating the expression of Peroxisome proliferator-activated receptor alpha (PPARA).	[42], [87]

BM-17.0744 [Discontinued in Phase 2]

In total 1 mechanisms lead to this potential drug response		Drug Info
Response Summary	Peroxisome proliferator-activated receptor alpha (PPARA) is a therapeutic target for BM-17.0744. The Wilms tumor 1-associating protein (WTAP) has potential in affecting the response of BM-17.0744 through regulating the expression of Peroxisome proliferator-activated receptor alpha (PPARA).	[6], [42]

BVT-142 [Terminated]

In total 1 mechanisms lead to this potential drug response		Drug Info
Response Summary	Peroxisome proliferator-activated receptor alpha (PPARA) is a therapeutic target for BVT-142. The Wilms tumor 1-associating protein (WTAP) has potential in affecting the response of BVT-142 through regulating the expression of Peroxisome proliferator-activated receptor alpha (PPARA).	[42], [88]

CS-204 [Terminated]

In total 1 mechanisms lead to this potential drug response		Drug Info
Response Summary	Peroxisome proliferator-activated receptor alpha (PPARA) is a therapeutic target for CS-204. The Wilms tumor 1-associating protein (WTAP) has potential in affecting the response of CS-204 through regulating the expression of Peroxisome proliferator-activated receptor alpha (PPARA).	[42], [89]

CS-207 [Terminated]

In total 1 mechanisms lead to this potential drug response		Drug Info
Response Summary	Peroxisome proliferator-activated receptor alpha (PPARA) is a therapeutic target for CS-207. The Wilms tumor 1-associating protein (WTAP) has potential in affecting the response of CS-207 through regulating the expression of Peroxisome proliferator-activated receptor alpha (PPARA).	[42], [90]

DRF 10945 [Discontinued in Phase 1]

In total 1 mechanisms lead to this potential drug response		Drug Info
Response Summary	Peroxisome proliferator-activated receptor alpha (PPARA) is a therapeutic target for DRF 10945. The Wilms tumor 1-associating protein (WTAP) has potential in affecting the response of DRF 10945 through regulating the expression of Peroxisome proliferator-activated receptor alpha (PPARA).	[42], [91]

E-3030 [Discontinued in Phase 1]

In total 1 mechanisms lead to this potential drug response		Drug Info
Response Summary	Peroxisome proliferator-activated receptor alpha (PPARA) is a therapeutic target for E-3030. The Wilms tumor 1-associating protein (WTAP) has potential in affecting the response of E-3030 through regulating the expression of Peroxisome proliferator-activated receptor alpha (PPARA).	[42], [92]

GSK-677954 [Discontinued in Phase 2]

In total 1 mechanisms lead to this potential drug response		Drug Info
Response Summary	Peroxisome proliferator-activated receptor alpha (PPARA) is a therapeutic target for GSK-677954. The Wilms tumor 1-associating protein (WTAP) has potential in affecting the response of GSK-677954 through regulating the expression of Peroxisome proliferator-activated receptor alpha (PPARA).	[42], [93]

Indeglitazar [Discontinued in Phase 2]

In total 1 mechanisms lead to this potential drug response		Drug Info
Response Summary	Peroxisome proliferator-activated receptor alpha (PPARA) is a therapeutic target for Indeglitazar. The Wilms tumor 1-associating protein (WTAP) has potential in affecting the response of Indeglitazar through regulating the expression of Peroxisome proliferator-activated receptor alpha (PPARA).	[42], [94]

KRP-101 [Discontinued in Phase 2]

In total 1 mechanisms lead to this potential drug response		Drug Info
Response Summary	Peroxisome proliferator-activated receptor alpha (PPARA) is a therapeutic target for KRP-101. The Wilms tumor 1-associating protein (WTAP) has potential in affecting the response of KRP-101 through regulating the expression of Peroxisome proliferator-activated receptor alpha (PPARA).	[42], [95]

KRP-105 [Terminated]

In total 1 mechanisms lead to this potential drug response		Drug Info
Response Summary	Peroxisome proliferator-activated receptor alpha (PPARA) is a therapeutic target for KRP-105. The Wilms tumor 1-associating protein (WTAP) has potential in affecting the response of KRP-105 through regulating the expression of Peroxisome proliferator-activated receptor alpha (PPARA).	[42], [51]

KRP-297 [Discontinued in Phase 2]

In total 1 mechanisms lead to this potential drug response		Drug Info
Response Summary	Peroxisome proliferator-activated receptor alpha (PPARA) is a therapeutic target for KRP-297. The Wilms tumor 1-associating protein (WTAP) has potential in affecting the response of KRP-297 through regulating the expression of Peroxisome proliferator-activated receptor alpha (PPARA).	[42], [81]

LG-101280 [Discontinued in Phase 1]

In total 1 mechanisms lead to this potential drug response		Drug Info
Response Summary	Peroxisome proliferator-activated receptor alpha (PPARA) is a therapeutic target for LG-101280. The Wilms tumor 1-associating protein (WTAP) has potential in affecting the response of LG-101280 through regulating the expression of Peroxisome proliferator-activated receptor alpha (PPARA).	[42], [96]

LY-929 [Discontinued in Phase 1]

In total 1 mechanisms lead to this potential drug response		Drug Info
Response Summary	Peroxisome proliferator-activated receptor alpha (PPARA) is a therapeutic target for LY-929. The Wilms tumor 1-associating protein (WTAP) has potential in affecting the response of LY-929 through regulating the expression of Peroxisome proliferator-activated receptor alpha (PPARA).	[42], [97]

MP-136 [Discontinued in Phase 1]

In total 1 mechanisms lead to this potential drug response		Drug Info
Response Summary	Peroxisome proliferator-activated receptor alpha (PPARA) is a therapeutic target for MP-136. The Wilms tumor 1-associating protein (WTAP) has potential in affecting the response of MP-136 through regulating the expression of Peroxisome proliferator-activated receptor alpha (PPARA).	[42], [98]

NS-220 [Discontinued in Phase 2]

In total 1 mechanisms lead to this potential drug response		Drug Info
Response Summary	Peroxisome proliferator-activated receptor alpha (PPARA) is a therapeutic target for NS-220. The Wilms tumor 1-associating protein (WTAP) has potential in affecting the response of NS-220 through regulating the expression of Peroxisome proliferator-activated receptor alpha (PPARA).	[42], [99]

Reglixane [Discontinued in Phase 2]

In total 1 mechanisms lead to this potential drug response		Drug Info
Response Summary	Peroxisome proliferator-activated receptor alpha (PPARA) is a therapeutic target for Reglixane. The Wilms tumor 1-associating protein (WTAP) has potential in affecting the response of Reglixane through regulating the expression of Peroxisome proliferator-activated receptor alpha (PPARA).	[42], [100]

Sipoglitazar [Terminated]

In total 1 mechanisms lead to this potential drug response		Drug Info
Response Summary	Peroxisome proliferator-activated receptor alpha (PPARA) is a therapeutic target for Sipoglitazar. The Wilms tumor 1-associating protein (WTAP) has potential in affecting the response of Sipoglitazar through regulating the expression of Peroxisome proliferator-activated receptor alpha (PPARA).	[42], [101]

Sodelglitazar [Discontinued in Phase 2]

In total 1 mechanisms lead to this potential drug response		Drug Info
Response Summary	Peroxisome proliferator-activated receptor alpha (PPARA) is a therapeutic target for Sodelglitazar. The Wilms tumor 1-associating protein (WTAP) has potential in affecting the response of Sodelglitazar through regulating the expression of Peroxisome proliferator-activated receptor alpha (PPARA).	[42], [102]

PI3-kinase beta (PIK3CB)

Buparlisib [Phase 3]

In total 1 mechanisms lead to this potential drug response		Drug Info
Response Summary	PI3-kinase beta (PIK3CB) is a therapeutic target for Buparlisib. The Wilms tumor 1-associating protein (WTAP) has potential in affecting the response of Buparlisib through regulating the expression of PI3-kinase beta (PIK3CB).	[70], [103]

PA-799 [Phase 1/2]

In total 1 mechanisms lead to this potential drug response		Drug Info
Response Summary	PI3-kinase beta (PIK3CB) is a therapeutic target for PA-799. The Wilms tumor 1-associating protein (WTAP) has potential in affecting the response of PA-799 through regulating the expression of PI3-kinase beta (PIK3CB).	[103], [104]

PQR309 [Phase 2]

In total 1 mechanisms lead to this potential drug response		Drug Info
Response Summary	PI3-kinase beta (PIK3CB) is a therapeutic target for PQR309. The Wilms tumor 1-associating protein (WTAP) has potential in affecting the response of PQR309 through regulating the expression of PI3-kinase beta (PIK3CB).	[103], [105]

AZD8186 [Phase 1]

In total 1 mechanisms lead to this potential drug response		Drug Info
Response Summary	PI3-kinase beta (PIK3CB) is a therapeutic target for AZD8186. The Wilms tumor 1-associating protein (WTAP) has potential in affecting the response of AZD8186 through regulating the expression of PI3-kinase beta (PIK3CB).	[103], [106]

BAY 1082439 [Phase 1]

In total 1 mechanisms lead to this potential drug response		Drug Info
Response Summary	PI3-kinase beta (PIK3CB) is a therapeutic target for BAY 1082439. The Wilms tumor 1-associating protein (WTAP) has potential in affecting the response of BAY 1082439 through regulating the expression of PI3-kinase beta (PIK3CB).	[103], [107]

GSK2636771 [Phase 1]

In total 1 mechanisms lead to this potential drug response		Drug Info
Response Summary	PI3-kinase beta (PIK3CB) is a therapeutic target for GSK2636771. The Wilms tumor 1-associating protein (WTAP) has potential in affecting the response of GSK2636771 through regulating the expression of PI3-kinase beta (PIK3CB).	[6], [103]

3-(4-morpholinothieno[3,2-d]pyrimidin-2-yl)phenol [Investigative]

In total 1 mechanisms lead to this potential drug response		Drug Info
Response Summary	PI3-kinase beta (PIK3CB) is a therapeutic target for 3-(4-morpholinothieno[3,2-d]pyrimidin-2-yl)phenol. The Wilms tumor 1-associating protein (WTAP) has potential in affecting the response of 3-(4-morpholinothieno[3,2-d]pyrimidin-2-yl)phenol through regulating the expression of PI3-kinase beta (PIK3CB).	[103], [108]

Ethyl 1-[(1H-benzimidazol-2(3H)one-5-yl)sulfonyl]-1H-pyrrole-2-carboxylate [Investigative]

In total 1 mechanisms lead to this potential drug response		Drug Info
Response Summary	PI3-kinase beta (PIK3CB) is a therapeutic target for Ethyl 1-[(1H-benzimidazol-2(3H)one-5-yl)sulfonyl]-1H-pyrrole-2-carboxylate. The Wilms tumor 1-associating protein (WTAP) has potential in affecting the response of Ethyl 1-[(1H-benzimidazol-2(3H)one-5-yl)sulfonyl]-1H-pyrrole-2-carboxylate through regulating the expression of PI3-kinase beta (PIK3CB).	[103], [109]

ISIS 31963 [Investigative]

In total 1 mechanisms lead to this potential drug response		Drug Info
Response Summary	PI3-kinase beta (PIK3CB) is a therapeutic target for ISIS 31963. The Wilms tumor 1-associating protein (WTAP) has potential in affecting the response of ISIS 31963 through regulating the expression of PI3-kinase beta (PIK3CB).	[103], [110]

ISIS 31982 [Investigative]

In total 1 mechanisms lead to this potential drug response		Drug Info
Response Summary	PI3-kinase beta (PIK3CB) is a therapeutic target for ISIS 31982. The Wilms tumor 1-associating protein (WTAP) has potential in affecting the response of ISIS 31982 through regulating the expression of PI3-kinase beta (PIK3CB).	[103], [110]

ISIS 31996 [Investigative]

In total 1 mechanisms lead to this potential drug response		Drug Info
Response Summary	PI3-kinase beta (PIK3CB) is a therapeutic target for ISIS 31996. The Wilms tumor 1-associating protein (WTAP) has potential in affecting the response of ISIS 31996 through regulating the expression of PI3-kinase beta (PIK3CB).	[103], [110]

ISIS 32000 [Investigative]

In total 1 mechanisms lead to this potential drug response		Drug Info
Response Summary	PI3-kinase beta (PIK3CB) is a therapeutic target for ISIS 32000. The Wilms tumor 1-associating protein (WTAP) has potential in affecting the response of ISIS 32000 through regulating the expression of PI3-kinase beta (PIK3CB).	[103], [110]

ISIS 32002 [Investigative]

In total 1 mechanisms lead to this potential drug response		Drug Info
Response Summary	PI3-kinase beta (PIK3CB) is a therapeutic target for ISIS 32002. The Wilms tumor 1-associating protein (WTAP) has potential in affecting the response of ISIS 32002 through regulating the expression of PI3-kinase beta (PIK3CB).	[103], [110]

ISIS 32003 [Investigative]

In total 1 mechanisms lead to this potential drug response		Drug Info
Response Summary	PI3-kinase beta (PIK3CB) is a therapeutic target for ISIS 32003. The Wilms tumor 1-associating protein (WTAP) has potential in affecting the response of ISIS 32003 through regulating the expression of PI3-kinase beta (PIK3CB).	[103], [110]

ISIS 32004 [Investigative]

In total 1 mechanisms lead to this potential drug response		Drug Info
Response Summary	PI3-kinase beta (PIK3CB) is a therapeutic target for ISIS 32004. The Wilms tumor 1-associating protein (WTAP) has potential in affecting the response of ISIS 32004 through regulating the expression of PI3-kinase beta (PIK3CB).	[103], [110]

ISIS 32005 [Investigative]

In total 1 mechanisms lead to this potential drug response		Drug Info
Response Summary	PI3-kinase beta (PIK3CB) is a therapeutic target for ISIS 32005. The Wilms tumor 1-associating protein (WTAP) has potential in affecting the response of ISIS 32005 through regulating the expression of PI3-kinase beta (PIK3CB).	[103], [110]

ISIS 32006 [Investigative]

In total 1 mechanisms lead to this potential drug response		Drug Info
Response Summary	PI3-kinase beta (PIK3CB) is a therapeutic target for ISIS 32006. The Wilms tumor 1-associating protein (WTAP) has potential in affecting the response of ISIS 32006 through regulating the expression of PI3-kinase beta (PIK3CB).	[103], [110]

ISIS 32008 [Investigative]

In total 1 mechanisms lead to this potential drug response		Drug Info
Response Summary	PI3-kinase beta (PIK3CB) is a therapeutic target for ISIS 32008. The Wilms tumor 1-associating protein (WTAP) has potential in affecting the response of ISIS 32008 through regulating the expression of PI3-kinase beta (PIK3CB).	[103], [110]

ISIS 32010 [Investigative]

In total 1 mechanisms lead to this potential drug response		Drug Info
Response Summary	PI3-kinase beta (PIK3CB) is a therapeutic target for ISIS 32010. The Wilms tumor 1-associating protein (WTAP) has potential in affecting the response of ISIS 32010 through regulating the expression of PI3-kinase beta (PIK3CB).	[103], [110]

ISIS 32014 [Investigative]

In total 1 mechanisms lead to this potential drug response		Drug Info
Response Summary	PI3-kinase beta (PIK3CB) is a therapeutic target for ISIS 32014. The Wilms tumor 1-associating protein (WTAP) has potential in affecting the response of ISIS 32014 through regulating the expression of PI3-kinase beta (PIK3CB).	[103], [110]

ISIS 32015 [Investigative]

In total 1 mechanisms lead to this potential drug response		Drug Info
Response Summary	PI3-kinase beta (PIK3CB) is a therapeutic target for ISIS 32015. The Wilms tumor 1-associating protein (WTAP) has potential in affecting the response of ISIS 32015 through regulating the expression of PI3-kinase beta (PIK3CB).	[103], [110]

ISIS 32020 [Investigative]

In total 1 mechanisms lead to this potential drug response		Drug Info
Response Summary	PI3-kinase beta (PIK3CB) is a therapeutic target for ISIS 32020. The Wilms tumor 1-associating protein (WTAP) has potential in affecting the response of ISIS 32020 through regulating the expression of PI3-kinase beta (PIK3CB).	[103], [110]

ISIS 32021 [Investigative]

In total 1 mechanisms lead to this potential drug response		Drug Info
Response Summary	PI3-kinase beta (PIK3CB) is a therapeutic target for ISIS 32021. The Wilms tumor 1-associating protein (WTAP) has potential in affecting the response of ISIS 32021 through regulating the expression of PI3-kinase beta (PIK3CB).	[103], [110]

ISIS 32024 [Investigative]

In total 1 mechanisms lead to this potential drug response		Drug Info
Response Summary	PI3-kinase beta (PIK3CB) is a therapeutic target for ISIS 32024. The Wilms tumor 1-associating protein (WTAP) has potential in affecting the response of ISIS 32024 through regulating the expression of PI3-kinase beta (PIK3CB).	[103], [110]

ISIS 32028 [Investigative]

In total 1 mechanisms lead to this potential drug response		Drug Info
Response Summary	PI3-kinase beta (PIK3CB) is a therapeutic target for ISIS 32028. The Wilms tumor 1-associating protein (WTAP) has potential in affecting the response of ISIS 32028 through regulating the expression of PI3-kinase beta (PIK3CB).	[103], [110]

ISIS 32035 [Investigative]

In total 1 mechanisms lead to this potential drug response		Drug Info
Response Summary	PI3-kinase beta (PIK3CB) is a therapeutic target for ISIS 32035. The Wilms tumor 1-associating protein (WTAP) has potential in affecting the response of ISIS 32035 through regulating the expression of PI3-kinase beta (PIK3CB).	[103], [110]

ISIS 32039 [Investigative]

In total 1 mechanisms lead to this potential drug response		Drug Info
Response Summary	PI3-kinase beta (PIK3CB) is a therapeutic target for ISIS 32039. The Wilms tumor 1-associating protein (WTAP) has potential in affecting the response of ISIS 32039 through regulating the expression of PI3-kinase beta (PIK3CB).	[103], [111]

KU-0060648 [Investigative]

In total 1 mechanisms lead to this potential drug response		Drug Info
Response Summary	PI3-kinase beta (PIK3CB) is a therapeutic target for KU-0060648. The Wilms tumor 1-associating protein (WTAP) has potential in affecting the response of KU-0060648 through regulating the expression of PI3-kinase beta (PIK3CB).	[103], [112]

LY-292223 [Investigative]

In total 1 mechanisms lead to this potential drug response		Drug Info
Response Summary	PI3-kinase beta (PIK3CB) is a therapeutic target for LY-292223. The Wilms tumor 1-associating protein (WTAP) has potential in affecting the response of LY-292223 through regulating the expression of PI3-kinase beta (PIK3CB).	[103], [111]

PI-3065 [Investigative]

In total 1 mechanisms lead to this potential drug response		Drug Info
Response Summary	PI3-kinase beta (PIK3CB) is a therapeutic target for PI-3065. The Wilms tumor 1-associating protein (WTAP) has potential in affecting the response of PI-3065 through regulating the expression of PI3-kinase beta (PIK3CB).	[103], [109]

PIK-75 [Investigative]

In total 1 mechanisms lead to this potential drug response		Drug Info
Response Summary	PI3-kinase beta (PIK3CB) is a therapeutic target for PIK-75. The Wilms tumor 1-associating protein (WTAP) has potential in affecting the response of PIK-75 through regulating the expression of PI3-kinase beta (PIK3CB).	[103], [113]

PP121 [Investigative]

In total 1 mechanisms lead to this potential drug response		Drug Info
Response Summary	PI3-kinase beta (PIK3CB) is a therapeutic target for PP121. The Wilms tumor 1-associating protein (WTAP) has potential in affecting the response of PP121 through regulating the expression of PI3-kinase beta (PIK3CB).	[103], [114]

TGX-221 [Investigative]

In total 1 mechanisms lead to this potential drug response		Drug Info
Response Summary	PI3-kinase beta (PIK3CB) is a therapeutic target for TGX-221. The Wilms tumor 1-associating protein (WTAP) has potential in affecting the response of TGX-221 through regulating the expression of PI3-kinase beta (PIK3CB).	[103], [115]

Proto-oncogene c-Myc (MYC)

AVI-5126 [Phase 2]

In total 1 mechanisms lead to this potential drug response		Drug Info
Response Summary	Proto-oncogene c-Myc (MYC) is a therapeutic target for AVI-5126. The Wilms tumor 1-associating protein (WTAP) has potential in affecting the response of AVI-5126 through regulating the expression of Proto-oncogene c-Myc (MYC).	[116], [117]

Resten-NG [Phase 2]

In total 1 mechanisms lead to this potential drug response		Drug Info
Response Summary	Proto-oncogene c-Myc (MYC) is a therapeutic target for Resten-NG. The Wilms tumor 1-associating protein (WTAP) has potential in affecting the response of Resten-NG through regulating the expression of Proto-oncogene c-Myc (MYC).	[116], [118]

TWS-119 [Investigative]

In total 1 mechanisms lead to this potential drug response		Drug Info
Response Summary	Proto-oncogene c-Myc (MYC) is a therapeutic target for TWS-119. The Wilms tumor 1-associating protein (WTAP) has potential in affecting the response of TWS-119 through regulating the expression of Proto-oncogene c-Myc (MYC).	[116], [119]

RIP2 messenger RNA (RIP2 mRNA)

ISIS-CRP [Phase 1]

In total 1 mechanisms lead to this potential drug response		Drug Info
Response Summary	RIP2 messenger RNA (RIP2 mRNA) is a therapeutic target for ISIS-CRP. The Wilms tumor 1-associating protein (WTAP) has potential in affecting the response of ISIS-CRP through regulating the expression of RIP2 messenger RNA (RIP2 mRNA).	[20], [120]

ISIS 104211 [Investigative]

In total 1 mechanisms lead to this potential drug response		Drug Info
Response Summary	RIP2 messenger RNA (RIP2 mRNA) is a therapeutic target for ISIS 104211. The Wilms tumor 1-associating protein (WTAP) has potential in affecting the response of ISIS 104211 through regulating the expression of RIP2 messenger RNA (RIP2 mRNA).	[20], [121]

ISIS 104253 [Investigative]

In total 1 mechanisms lead to this potential drug response		Drug Info
Response Summary	RIP2 messenger RNA (RIP2 mRNA) is a therapeutic target for ISIS 104253. The Wilms tumor 1-associating protein (WTAP) has potential in affecting the response of ISIS 104253 through regulating the expression of RIP2 messenger RNA (RIP2 mRNA).	[20], [121]

ISIS 104254 [Investigative]

In total 1 mechanisms lead to this potential drug response		Drug Info
Response Summary	RIP2 messenger RNA (RIP2 mRNA) is a therapeutic target for ISIS 104254. The Wilms tumor 1-associating protein (WTAP) has potential in affecting the response of ISIS 104254 through regulating the expression of RIP2 messenger RNA (RIP2 mRNA).	[20], [121]

ISIS 104255 [Investigative]

In total 1 mechanisms lead to this potential drug response		Drug Info
Response Summary	RIP2 messenger RNA (RIP2 mRNA) is a therapeutic target for ISIS 104255. The Wilms tumor 1-associating protein (WTAP) has potential in affecting the response of ISIS 104255 through regulating the expression of RIP2 messenger RNA (RIP2 mRNA).	[20], [121]

ISIS 104256 [Investigative]

In total 1 mechanisms lead to this potential drug response		Drug Info
Response Summary	RIP2 messenger RNA (RIP2 mRNA) is a therapeutic target for ISIS 104256. The Wilms tumor 1-associating protein (WTAP) has potential in affecting the response of ISIS 104256 through regulating the expression of RIP2 messenger RNA (RIP2 mRNA).	[20], [121]

ISIS 104257 [Investigative]

In total 1 mechanisms lead to this potential drug response		Drug Info
Response Summary	RIP2 messenger RNA (RIP2 mRNA) is a therapeutic target for ISIS 104257. The Wilms tumor 1-associating protein (WTAP) has potential in affecting the response of ISIS 104257 through regulating the expression of RIP2 messenger RNA (RIP2 mRNA).	[20], [121]

ISIS 104258 [Investigative]

In total 1 mechanisms lead to this potential drug response		Drug Info
Response Summary	RIP2 messenger RNA (RIP2 mRNA) is a therapeutic target for ISIS 104258. The Wilms tumor 1-associating protein (WTAP) has potential in affecting the response of ISIS 104258 through regulating the expression of RIP2 messenger RNA (RIP2 mRNA).	[20], [122]

NM-PP1 [Investigative]

In total 1 mechanisms lead to this potential drug response		Drug Info
Response Summary	RIP2 messenger RNA (RIP2 mRNA) is a therapeutic target for NM-PP1. The Wilms tumor 1-associating protein (WTAP) has potential in affecting the response of NM-PP1 through regulating the expression of RIP2 messenger RNA (RIP2 mRNA).	[20], [122]

Src kinase inhibitor I [Investigative]

In total 1 mechanisms lead to this potential drug response		Drug Info
Response Summary	RIP2 messenger RNA (RIP2 mRNA) is a therapeutic target for Src kinase inhibitor I. The Wilms tumor 1-associating protein (WTAP) has potential in affecting the response of Src kinase inhibitor I through regulating the expression of RIP2 messenger RNA (RIP2 mRNA).	[20], [121]

TRAIL receptor 1 (TRAIL-R1)

Mapatumumab [Phase 2]

In total 1 mechanisms lead to this potential drug response		Drug Info
Response Summary	TRAIL receptor 1 (TRAIL-R1) is a therapeutic target for Mapatumumab. The Wilms tumor 1-associating protein (WTAP) has potential in affecting the response of Mapatumumab through regulating the expression of TRAIL receptor 1 (TRAIL-R1).	[20], [123]

References

Ref 1	WTAP facilitates progression of endometrial cancer via CAV-1/NF-KappaB axis. Cell Biol Int. 2021 Jun;45(6):1269-1277. doi: 10.1002/cbin.11570. Epub 2021 Feb 19.
Ref 2	ClinicalTrials.gov (NCT03672305) Clinical Study on the Efficacy and Safety of c-Met/PD-L1 CAR-T Cell Injection in the Treatment of HCC
Ref 3	Clinical pipeline report, company report or official report of Catabasis Pharmaceuticals Inc.
Ref 4	WT1 associated protein promotes metastasis and chemo-resistance to gemcitabine by stabilizing Fak mRNA in pancreatic cancer. Cancer Lett. 2019 Jun 1;451:48-57. doi: 10.1016/j.canlet.2019.02.043. Epub 2019 Mar 6.
Ref 5	Inhibitors of JAK-family kinases: an update on the patent literature 2013-2015, part 1. Expert Opin Ther Pat. 2017 Feb;27(2):127-143. doi: 10.1080/13543776.2017.1252753. Epub 2016 Nov 7.
Ref 6	Interpreting expression profiles of cancers by genome-wide survey of breadth of expression in normal tissues. Genomics. 2005 Aug;86(2):127-41. doi: 10.1016/j.ygeno.2005.04.008.
Ref 7	Clinical pipeline report, company report or official report of InxMed.
Ref 8	FAK Inhibition disrupts a Beta5 integrin signaling axis controlling anchorage-independent ovarian carcinoma growth. Mol Cancer Ther. 2014 Aug;13(8):2050-61. doi: 10.1158/1535-7163.MCT-13-1063. Epub 2014 Jun 4.
Ref 9	Role of focal adhesion kinase in regulating YB-1-mediated paclitaxel resistance in ovarian cancer. J Natl Cancer Inst. 2013 Oct 2;105(19):1485-95. doi: 10.1093/jnci/djt210. Epub 2013 Sep 23.
Ref 10	Inhibition of focal adhesion kinase by PF-562,271 inhibits the growth and metastasis of pancreatic cancer concomitant with altering the tumor microenvironment. Mol Cancer Ther. 2011 Nov;10(11):2135-45. doi: 10.1158/1535-7163.MCT-11-0261. Epub 2011 Sep 8.
Ref 11	Cellular characterization of a novel focal adhesion kinase inhibitor. J Biol Chem. 2007 May 18;282(20):14845-52. doi: 10.1074/jbc.M606695200. Epub 2007 Mar 28.
Ref 12	A small molecule FAK kinase inhibitor, GSK2256098, inhibits growth and survival of pancreatic ductal adenocarcinoma cells. Cell Cycle. 2014;13(19):3143-9. doi: 10.4161/15384101.2014.949550.
Ref 13	N(6)-methyladenosine methyltransferase WTAP-stabilized FOXD2-AS1 promotes the osteosarcoma progression through m(6)A/FOXM1 axis. Bioengineered. 2022 Apr;13(4):7963-7973. doi: 10.1080/21655979.2021.2008218.
Ref 14	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1443).
Ref 15	The m(6)A-methylase complex recruits TREX and regulates mRNA export. Sci Rep. 2018 Sep 14;8(1):13827. doi: 10.1038/s41598-018-32310-8.
Ref 16	US patent application no. 7,427,470, Antisense modulation of helicase-moi expression.
Ref 17	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
Ref 18	N(6)-methyladenosine (m(6)A) methyltransferase WTAP accelerates the Warburg effect of gastric cancer through regulating HK2 stability. Biomed Pharmacother. 2021 Jan;133:111075. doi: 10.1016/j.biopha.2020.111075. Epub 2020 Dec 9.
Ref 19	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2019).
Ref 20	Transcriptome-Wide High-Throughput m6A Sequencing of Differential m6A Methylation Patterns in the Human Rheumatoid Arthritis Fibroblast-Like Synoviocytes Cell Line MH7A. J Inflamm Res. 2021 Feb 25;14:575-586. doi: 10.2147/JIR.S296006. eCollection 2021.
Ref 21	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015
Ref 22	Selective JAK inhibitors in development for rheumatoid arthritis. Expert Opin Investig Drugs. 2014 Aug;23(8):1067-77. doi: 10.1517/13543784.2014.918604. Epub 2014 May 12.
Ref 23	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2049).
Ref 24	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
Ref 25	Clinical pipeline report, company report or official report of Aclaris Therapeutics.
Ref 26	ClinicalTrials.gov (NCT03759340) ATI-502 Topical Solution for the Treatment of Alopecia Areata (AA), Alopecia Universalis (AU) and Alopecia Totalis (AT). U.S. National Institutes of Health.
Ref 27	Janus kinase 2 inhibitors. Synthesis and characterization of a novel polycyclic azaindole. J Med Chem. 2009 Dec 24;52(24):7938-41. doi: 10.1021/jm901383u.
Ref 28	Emerging drugs for psoriasis. Expert Opin Emerg Drugs. 2009 Mar;14(1):145-63. doi: 10.1517/14728210902771334.
Ref 29	The specificity of JAK3 kinase inhibitors. Blood. 2008 Feb 15;111(4):2155-7. doi: 10.1182/blood-2007-09-115030. Epub 2007 Dec 19.
Ref 30	Discovery of aminoquinazolines as potent, orally bioavailable inhibitors of Lck: synthesis, SAR, and in vivo anti-inflammatory activity. J Med Chem. 2006 Sep 21;49(19):5671-86. doi: 10.1021/jm0605482.
Ref 31	Photochemical preparation of a pyridone containing tetracycle: a Jak protein kinase inhibitor. Bioorg Med Chem Lett. 2002 Apr 22;12(8):1219-23. doi: 10.1016/s0960-894x(02)00106-3.
Ref 32	Naphthyl ketones: a new class of Janus kinase 3 inhibitors. Bioorg Med Chem Lett. 2000 Mar 20;10(6):575-9. doi: 10.1016/s0960-894x(00)00051-2.
Ref 33	Discovery of 1-methyl-1H-imidazole derivatives as potent Jak2 inhibitors. J Med Chem. 2014 Jan 9;57(1):144-58. doi: 10.1021/jm401546n. Epub 2013 Dec 20.
Ref 34	Immunotherapy for De Novo renal transplantation: what's in the pipeline?. Drugs. 2006;66(13):1665-84. doi: 10.2165/00003495-200666130-00002.
Ref 35	Selective inhibitor of Janus tyrosine kinase 3, PNU156804, prolongs allograft survival and acts synergistically with cyclosporine but additively with rapamycin. Blood. 2002 Jan 15;99(2):680-9. doi: 10.1182/blood.v99.2.680.
Ref 36	mTORC1-chaperonin CCT signaling regulates m(6)A RNA methylation to suppress autophagy. Proc Natl Acad Sci U S A. 2021 Mar 9;118(10):e2021945118. doi: 10.1073/pnas.2021945118.
Ref 37	PPARGamma ligands and their therapeutic applications: a patent review (2008 - 2014). Expert Opin Ther Pat. 2015 Feb;25(2):175-91. doi: 10.1517/13543776.2014.985206. Epub 2014 Nov 21.
Ref 38	Constrained peptides' time to shine?. Nat Rev Drug Discov. 2018 Jul 30;17(8):531-533. doi: 10.1038/nrd.2018.125.
Ref 39	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
Ref 40	Dual mTORC1 and mTORC2 inhibitor Palomid 529 penetrates the blood-brain barrier without restriction by ABCB1 and ABCG2. Int J Cancer. 2013 Sep 1;133(5):1222-33. doi: 10.1002/ijc.28126. Epub 2013 Apr 1.
Ref 41	Sestrin modulator NV-5138 produces rapid antidepressant effects via direct mTORC1 activation. J Clin Invest. 2019 Apr 16;129(6):2542-2554. doi: 10.1172/JCI126859.
Ref 42	A METTL3-METTL14 complex mediates mammalian nuclear RNA N6-adenosine methylation. Nat Chem Biol. 2014 Feb;10(2):93-5. doi: 10.1038/nchembio.1432. Epub 2013 Dec 6.
Ref 43	Peroxisome proliferator-activated receptor alpha activators improve insulin sensitivity and reduce adiposity. J Biol Chem. 2000 Jun 2;275(22):16638-42. doi: 10.1074/jbc.275.22.16638.
Ref 44	Muraglitazar, a dual (alpha/gamma) PPAR activator: a randomized, double-blind, placebo-controlled, 24-week monotherapy trial in adult patients with type 2 diabetes. Clin Ther. 2005 Aug;27(8):1181-95. doi: 10.1016/j.clinthera.2005.08.005.
Ref 45	Bezafibrate at clinically relevant doses decreases serum/liver triglycerides via down-regulation of sterol regulatory element-binding protein-1c in mice: a novel peroxisome proliferator-activated receptor alpha-independent mechanism. Mol Pharmacol. 2009 Apr;75(4):782-92. doi: 10.1124/mol.108.052928. Epub 2009 Jan 5.
Ref 46	Pemafibrate: First Global Approval. Drugs. 2017 Oct;77(16):1805-1810. doi: 10.1007/s40265-017-0818-x.
Ref 47	Tesaglitazar, a dual PPAR-Alpha/Gamma agonist, hamster carcinogenicity, investigative animal and clinical studies. Toxicol Pathol. 2012;40(1):18-32. doi: 10.1177/0192623311429972. Epub 2011 Nov 30.
Ref 48	Ragaglitazar: the pharmacokinetics, pharmacodynamics, and tolerability of a novel dual PPAR alpha and gamma agonist in healthy subjects and patients with type 2 diabetes. J Clin Pharmacol. 2003 Nov;43(11):1244-56. doi: 10.1177/0091270003257230.
Ref 49	Tolerability and pharmacokinetics of lobeglitazone, a novel peroxisome proliferator-activated receptor-Gamma agonist, after a single oral administration in healthy female subjects. Clin Drug Investig. 2014 Jul;34(7):467-74. doi: 10.1007/s40261-014-0197-y.
Ref 50	Determination of chiglitazar, a dual alpha/gamma peroxisome proliferator-activated receptor (PPAR) agonist, in human plasma by liquid chromatography-tandem mass spectrometry. Pharmazie. 2007 Nov;62(11):825-9.
Ref 51	Pharmacokinetics, safety, and tolerability of saroglitazar (ZYH1), a predominantly PPARAlpha agonist with moderate PPARGamma agonist activity in healthy human subjects. Clin Drug Investig. 2013 Nov;33(11):809-16. doi: 10.1007/s40261-013-0128-3.
Ref 52	A novel oxyiminoalkanoic acid derivative, TAK-559, activates human peroxisome proliferator-activated receptor subtypes. Eur J Pharmacol. 2004 Jul 8;495(1):17-26. doi: 10.1016/j.ejphar.2004.05.020.
Ref 53	The disposition and metabolism of naveglitazar, a peroxisome proliferator-activated receptor alpha-gamma dual, gamma-dominant agonist in mice, rats, and monkeys. Drug Metab Dispos. 2007 Jan;35(1):51-61. doi: 10.1124/dmd.106.012328. Epub 2006 Sep 29.
Ref 54	Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800024296)
Ref 55	Clinical pipeline report, company report or official report of Zydus Cadila.
Ref 56	Dual peroxisome proliferator-activated receptor Alpha/Delta agonist GFT505 improves hepatic and peripheral insulin sensitivity in abdominally obese subjects. Diabetes Care. 2013 Oct;36(10):2923-30. doi: 10.2337/dc12-2012. Epub 2013 May 28.
Ref 57	Mechanism of action of fibrates on lipid and lipoprotein metabolism. Circulation. 1998 Nov 10;98(19):2088-93. doi: 10.1161/01.cir.98.19.2088.
Ref 58	Therapeutic potential of aleglitazar, a new dual PPAR-Alpha/Gamma agonist: implications for cardiovascular disease in patients with diabetes mellitus. Am J Cardiovasc Drugs. 2010;10(4):209-16. doi: 10.2165/11539500-000000000-00000.
Ref 59	Clinical pipeline report, company report or official report of Tempest Therapeutics.
Ref 60	Design novel dual agonists for treating type-2 diabetes by targeting peroxisome proliferator-activated receptors with core hopping approach. PLoS One. 2012;7(6):e38546. doi: 10.1371/journal.pone.0038546. Epub 2012 Jun 7.
Ref 61	Potent and selective PPAR-alpha agonist LY518674 upregulates both ApoA-I production and catabolism in human subjects with the metabolic syndrome. Arterioscler Thromb Vasc Biol. 2009 Jan;29(1):140-6. doi: 10.1161/ATVBAHA.108.171223. Epub 2008 Nov 6.
Ref 62	Fibrates as therapy for osteoarthritis and rheumatoid arthritis A systematic review. Ther Adv Musculoskelet Dis. 2013 February; 5(1): 33-44.
Ref 63	Peroxisome proliferator-activated receptors, metabolic syndrome and cardiovascular disease. Future Cardiol. 2010 September; 6(5): 657-691.
Ref 64	Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800021175)
Ref 65	Discovery of an oxybenzylglycine based peroxisome proliferator activated receptor alpha selective agonist 2-((3-((2-(4-chlorophenyl)-5-methyloxazol-4-yl)methoxy)benzyl)(methoxycarbonyl)amino)acetic acid (BMS-687453). J Med Chem. 2010 Apr 8;53(7):2854-64. doi: 10.1021/jm9016812.
Ref 66	Activation of peroxisome proliferator-activated receptor gamma (PPARgamma) by nitroalkene fatty acids: importance of nitration position and degree of unsaturation. J Med Chem. 2009 Aug 13;52(15):4631-9. doi: 10.1021/jm900326c.
Ref 67	Pharmacological profiles of a novel oral antidiabetic agent, JTT-501, an isoxazolidinedione derivative. Eur J Pharmacol. 1999 Jan 8;364(2-3):211-9. doi: 10.1016/s0014-2999(98)00832-2.
Ref 68	Molecular characterization of novel and selective peroxisome proliferator-activated receptor alpha agonists with robust hypolipidemic activity in vivo. Mol Pharmacol. 2009 Feb;75(2):296-306. doi: 10.1124/mol.108.051656. Epub 2008 Oct 29.
Ref 69	PPAR-alpha and -gamma but not -delta agonists inhibit airway inflammation in a murine model of asthma: in vitro evidence for an NF-kappaB-independent effect. Br J Pharmacol. 2003 May;139(1):163-71. doi: 10.1038/sj.bjp.0705232.
Ref 70	How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
Ref 71	A new class of peroxisome proliferator-activated receptor agonists with a novel binding epitope shows antidiabetic effects. J Biol Chem. 2004 Sep 24;279(39):41124-30. doi: 10.1074/jbc.M401552200. Epub 2004 Jul 15.
Ref 72	Emerging antidyslipidemic drugs. Expert Opin Emerg Drugs. 2008 Jun;13(2):363-81. doi: 10.1517/14728214.13.2.363.
Ref 73	PPAR alpha structure-function relationships derived from species-specific differences in responsiveness to hypolipidemic agents. Biol Chem. 1997 Jul;378(7):651-5. doi: 10.1515/bchm.1997.378.7.651.
Ref 74	Design and synthesis of alpha-aryloxy-alpha-methylhydrocinnamic acids: a novel class of dual peroxisome proliferator-activated receptor alpha/gamma agonists. J Med Chem. 2004 May 6;47(10):2422-5. doi: 10.1021/jm0342616.
Ref 75	Phenylacetic acid derivatives as hPPAR agonists. Bioorg Med Chem Lett. 2003 Apr 7;13(7):1277-80. doi: 10.1016/s0960-894x(03)00115-x.
Ref 76	The ChEMBL database in 2017. Nucleic Acids Res. 2017 Jan 4;45(D1):D945-D954.
Ref 77	Oleoylethanolamide, an endogenous PPAR-alpha agonist, lowers body weight and hyperlipidemia in obese rats. Neuropharmacology. 2005 Jun;48(8):1147-53. doi: 10.1016/j.neuropharm.2005.02.013. Epub 2005 Apr 21.
Ref 78	Identification of a subtype selective human PPARalpha agonist through parallel-array synthesis. Bioorg Med Chem Lett. 2001 May 7;11(9):1225-7. doi: 10.1016/s0960-894x(01)00188-3.
Ref 79	Pristanic acid and phytanic acid: naturally occurring ligands for the nuclear receptor peroxisome proliferator-activated receptor alpha. J Lipid Res. 2000 Nov;41(11):1801-7.
Ref 80	A novel peroxisome proliferator-activated receptor alpha/gamma dual agonist demonstrates favorable effects on lipid homeostasis. Endocrinology. 2004 Apr;145(4):1640-8. doi: 10.1210/en.2003-1270. Epub 2003 Dec 30.
Ref 81	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 593).
Ref 82	Differential activation of peroxisome proliferator-activated receptors by eicosanoids. J Biol Chem. 1995 Oct 13;270(41):23975-83. doi: 10.1074/jbc.270.41.23975.
Ref 83	Antidiabetic and hypolipidemic potential of DRF 2519--a dual activator of PPAR-alpha and PPAR-gamma. Eur J Pharmacol. 2004 May 3;491(2-3):195-206. doi: 10.1016/j.ejphar.2004.03.034.
Ref 84	CN patent application no. 102459215, 3-(4-aminophenyl)-2-furancarboxylic acid derivative and pharmaceutically acceptable salt thereof.
Ref 85	Pharma & Vaccines. Product Development Pipeline. April 29 2009.
Ref 86	Docking and molecular dynamics simulations of peroxisome proliferator activated receptors interacting with pan agonist sodelglitazar. Protein Pept Lett. 2011 Oct;18(10):1021-7. doi: 10.2174/092986611796378701.
Ref 87	Identification of a functional peroxisome proliferator-activated receptor (PPAR) response element (PPRE) in the human apolipoprotein A-IV gene. Biochem Pharmacol. 2009 Sep 1;78(5):523-30. doi: 10.1016/j.bcp.2009.05.007. Epub 2009 May 9.
Ref 88	Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800026848)
Ref 89	O-arylmandelic acids as highly selective human PPAR alpha/gamma agonists. Bioorg Med Chem Lett. 2003 Oct 6;13(19):3185-90. doi: 10.1016/s0960-894x(03)00702-9.
Ref 90	Discovery of cyclic amine-substituted benzoic acids as PPARAlpha agonists. Bioorg Med Chem Lett. 2012 Jan 1;22(1):334-8. doi: 10.1016/j.bmcl.2011.11.002. Epub 2011 Nov 9.
Ref 91	A peroxisome proliferator-activated receptor alpha/gamma dual agonist with a unique in vitro profile and potent glucose and lipid effects in rodent models of type 2 diabetes and dyslipidemia. Mol Endocrinol. 2005 Jun;19(6):1593-605. doi: 10.1210/me.2005-0015. Epub 2005 Apr 14.
Ref 92	Emerging drugs for non-alcoholic fatty liver disease. Expert Opin Emerg Drugs. 2008 Mar;13(1):145-58. doi: 10.1517/14728214.13.1.145.
Ref 93	Modulation of PPAR receptor subtype selectivity of the ligands: aliphatic chain vs aromatic ring as a spacer between pharmacophore and the lipophilic moiety. Bioorg Med Chem Lett. 2008 Dec 15;18(24):6471-5. doi: 10.1016/j.bmcl.2008.10.062. Epub 2008 Oct 17.
Ref 94	Clinical pipeline report, company report or official report of Roche (2009).
Ref 95	Cardiac function and metabolism in Type 2 diabetic mice after treatment with BM 17.0744, a novel PPAR-alpha activator. Am J Physiol Heart Circ Physiol. 2002 Sep;283(3):H949-57. doi: 10.1152/ajpheart.00226.2001.
Ref 96	CN patent application no. 1882326, Ppar agonists for the treatment of hcv infection.
Ref 97	CN patent application no. 100577175, Combination therapy comprising glucose reabsorption inhibitors and PPAR modulators.
Ref 98	Antidiabetic and hypolipidemic effects of a novel dual peroxisome proliferator-activated receptor (PPAR) alpha/gamma agonist, E3030, in db/db mice and beagle dogs. J Pharmacol Sci. 2008 Sep;108(1):40-8. doi: 10.1254/jphs.fp0072346. Epub 2008 Sep 6.
Ref 99	The peroxisome proliferator-activated receptor-alpha (PPAR-alpha) agonist, AVE8134, attenuates the progression of heart failure and increases survival in rats. Acta Pharmacol Sin. 2009 Jul;30(7):935-46. doi: 10.1038/aps.2009.58. Epub 2009 Jun 8.
Ref 100	DOI: 10.1038/scibx.2012.669
Ref 101	Peroxisome Proliferators-Activated Receptor (PPAR) Modulators and Metabolic Disorders. PPAR Res. 2008; 2008: 679137.
Ref 102	Scaffold-based discovery of indeglitazar, a PPAR pan-active anti-diabetic agent. Proc Natl Acad Sci U S A. 2009 Jan 6;106(1):262-7. doi: 10.1073/pnas.0811325106. Epub 2008 Dec 30.
Ref 103	N(6)-methyladenosine mRNA methylation of PIK3CB regulates AKT signalling to promote PTEN-deficient pancreatic cancer progression. Gut. 2020 Dec;69(12):2180-2192. doi: 10.1136/gutjnl-2019-320179. Epub 2020 Apr 20.
Ref 104	1-substituted (Dibenzo[b,d]thiophen-4-yl)-2-morpholino-4H-chromen-4-ones endowed with dual DNA-PK/PI3-K inhibitory activity. J Med Chem. 2013 Aug 22;56(16):6386-401. doi: 10.1021/jm400915j. Epub 2013 Aug 1.
Ref 105	Targeting the phosphoinositide 3-kinase pathway in cancer. Nat Rev Drug Discov. 2009 Aug;8(8):627-44. doi: 10.1038/nrd2926.
Ref 106	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7967).
Ref 107	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2154).
Ref 108	Over-expression of clusterin is a resistance factor to the anti-cancer effect of histone deacetylase inhibitors. Eur J Cancer. 2009 Jul;45(10):1846-54. doi: 10.1016/j.ejca.2009.03.002. Epub 2009 Apr 1.
Ref 109	Synthesis and biological evaluation of sulfonylhydrazone-substituted imidazo[1,2-a]pyridines as novel PI3 kinase p110alpha inhibitors. Bioorg Med Chem. 2007 Sep 1;15(17):5837-44. doi: 10.1016/j.bmc.2007.05.070. Epub 2007 Jun 6.
Ref 110	US patent application no. 6,133,032, Antisense modulation of PI3 kinase p110 beta expression.
Ref 111	LY294002-geldanamycin heterodimers as selective inhibitors of the PI3K and PI3K-related family. Bioorg Med Chem Lett. 2001 Apr 9;11(7):909-13. doi: 10.1016/s0960-894x(01)00099-3.
Ref 112	PI 3-kinase p110beta: a new target for antithrombotic therapy. Nat Med. 2005 May;11(5):507-14. doi: 10.1038/nm1232. Epub 2005 Apr 17.
Ref 113	Targeted polypharmacology: discovery of dual inhibitors of tyrosine and phosphoinositide kinases. Nat Chem Biol. 2008 Nov;4(11):691-9. doi: 10.1038/nchembio.117. Epub 2008 Oct 12.
Ref 114	Human target validation of phosphoinositide 3-kinase (PI3K)beta: effects on platelets and insulin sensitivity, using AZD6482 a novel PI3Kbeta inhibitor. J Thromb Haemost. 2012 Oct;10(10):2127-36.
Ref 115	Inactivation of PI(3)K p110Delta breaks regulatory T-cell-mediated immune tolerance to cancer. Nature. 2014 Jun 19;510(7505):407-411. doi: 10.1038/nature13444. Epub 2014 Jun 11.
Ref 116	High Wilms' tumor 1 associating protein expression predicts poor prognosis in acute myeloid leukemia and regulates m(6)A methylation of MYC mRNA. J Cancer Res Clin Oncol. 2021 Jan;147(1):33-47. doi: 10.1007/s00432-020-03373-w. Epub 2020 Sep 3.
Ref 117	Local delivery of c-myc neutrally charged antisense oligonucleotides with transport catheter inhibits myointimal hyperplasia and positively affects vascular remodeling in the rabbit balloon injury model. Catheter Cardiovasc Interv. 2001 Oct;54(2):247-56. doi: 10.1002/ccd.1277.
Ref 118	Liposarcoma: molecular genetics and therapeutics. Sarcoma. 2011;2011:483154. doi: 10.1155/2011/483154. Epub 2010 Dec 27.
Ref 119	Anti-ageing pipeline starts to mature. Nat Rev Drug Discov. 2018 Sep;17(9):609-612. doi: 10.1038/nrd.2018.134. Epub 2018 Aug 3.
Ref 120	Selective inhibition of methoxyflavonoids on human CYP1B1 activity. Bioorg Med Chem. 2010 Sep 1;18(17):6310-5. doi: 10.1016/j.bmc.2010.07.020. Epub 2010 Jul 13.
Ref 121	US patent application no. 6,426,221, Antisense modulation of RIP2 expression.
Ref 122	The selectivity of protein kinase inhibitors: a further update. Biochem J. 2007 Dec 15;408(3):297-315. doi: 10.1042/BJ20070797.
Ref 123	BioPartnering North America--Programs from Pharma in Europe and the Middle East. IDrugs. 2010 Mar;13(3):162-5.

m6A Regulator and Potential Drug Response

Cite M6AREG

Correspondence

Prof. Feng ZHU

Prof. Shuiping Liu

Visitor Map